Fibroblast growth factor 21 (FGF21) is a PPAR-a-regulated metabolic regulator that plays critical roles in glucose homoeostasis, lipid metabolism, insulin sensitivity and obesity. Conjugated linoleic acids (CLA), especially trans-10 (t-10), cis-12 (c-12), have shown anti-obesity properties. In addition, CLA is reported as a high-affinity ligand and activator of PPAR-a. This raises the possibility that FGF21 might be involved in the anti-obesity effect of CLA. In the present study, we tested the hypothesis that FGF21 expression in the liver could be induced by t-10, c-12-CLA through PPAR-a. HepG2 cells were treated with 100 mM-bovine serum albumin, 10 mM-t-10, c-12-CLA or 100 mM-t-10, c-12-CLA for 8 h. A total of ten adult C57BL/6J mice were fed with the diets containing 1 % soya oil or t-10, c-12-CLA for 5 d. t-10, c-12-CLA stimulated hepatic FGF21 mRNA abundance as determined by real-time RT-PCR. t-10, c-12-CLA also increased serum FGF21 concentrations as measured by an ELISA. Co-transfection analysis indicated that reporter gene expression from the mouse FGF21 promoter was induced by t-10, c-12-CLA in a PPAR-a-dependent manner. Taken together, these results suggest that t-10, c-12-CLA induces hepatic FGF21 expression through PPAR-a. This FGF21 and PPAR-a linkage may provide another potential explanation for the anti-obesity effect of t-10, c-12-CLA.
Fibroblast growth factor 21 (FGF21), whose expression can be induced by PPAR-a activation in the liver (1 -3) , is a novel metabolic regulator that plays critical roles in glucose homoeostasis, lipid metabolism, insulin sensitivity and obesity (4, 5) .
Transgenic mice overexpressing FGF21 are resistant to diet-induced obesity (5) . Systemic administration of FGF21 to obese mice also reduced serum TAG levels, liver steatosis, as well as body weight and adiposity (6) . Conjugated linoleic acids (CLA) are positional and geometric conjugated dienoic isomers of linoleic acid. The cis-9, trans-11-CLA and trans-10 (t-10), cis-12 (c-12)-CLA possess biological activity (7) . Many studies (8 -10) have shown that CLA has anti-obesity effects, and t-10, c-12-CLA is specifically responsible for the anti-obesity benefit (11, 12) . Although much attention has been focused on the anti-obesity properties of CLA, the underlying mechanism still remains elusive. CLA is now recognised as a high-affinity ligand and activator of PPAR-a (13, 14) . This notion raises the possibility that FGF21 might be involved in the anti-obesity effect of CLA.
In the present study, we tested the hypothesis that FGF21 expression in the liver is induced by t-10, c-12-CLA. We also investigated the role of PPAR-a in the t-10, c-12-CLA induction of FGF21 expression.
Experimental methods

Preparation of conjugated linoleic acid -bovine serum albumin complexes
Fatty acid-free bovine serum albumin (BSA) was purchased from Sigma-Aldrich (St Louis, MO, USA). CLA -BSA complexes were prepared as reported (15) . Briefly, 10 mmol t-10, c-12-CLA (Natural Lipids Limited, Hovdebygda, Norway) were dissolved in 0·1 M-KOH solution together with 10 mmol BSA solution in PBS, and then incubated overnight at 48C.
The pH and volume were subsequently adjusted to 7·2 and 5·0 ml, respectively. After filter sterilisation, these complexes were ready to use.
Cell culture
The HepG2 cell line was maintained in minimum essential medium (MEM; Sigma-Aldrich) plus 10 % fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA), 2 mM of L-glutamine, 100 U/ml of penicillin and 100 mg/ml of streptomycin (Mediatech Inc., Manassas, VA, USA) at 378C in a 5 % CO 2 humidified atmosphere. When the cells were 70 % confluent, they were plated into six-well plates at 5 £ 10 5 per well and cultured. After 24 h incubation, the cells were serum starved for 16 h; the medium was then replaced by MEM plus 100 mM-BSA, 10 mM-t-10, c-12-CLA or 100 mM-t-10, c-12-CLA for 8 h.
Animal experiment
The animal-related protocols were approved by Sichuan Agricultural University Institutional Animal Care and Use Committee. A total of ten 12-week-old male C57BL/6J mice were housed at 228C on timed 12 h light -12 h dark cycles and had free access to diets and water. The mice were blocked by initial body weight and assigned into two treatment diets. The mice (n 5) were fed with a control diet with 1 % soya oil or a diet containing 1 % t-10, c-12-CLA. After 5 d of the treatment, postprandial mice were anaesthetised and bled between 07.00 and 08.00 hours. The livers were collected and frozen for RNA extraction. Serum samples were prepared and stored at 2 208C for future measurements.
RNA extraction and real-time RT-PCR
Total RNA from HepG2 cells and mouse liver tissue were extracted using TRIzol reagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer's instruction. RNA concentration and quality were determined by spectrophotometry. The cDNA was synthesised from 1 mg total RNA using random primers and RT (Promega, Madison, WI, USA). Real-time quantitative PCR were performed using Power SYBR Green PCR master mix (Applied Biosystems, Foster City, CA, USA) on an Applied Biosystems 7500 realtime PCR system. The conditions for these PCR were forty cycles of 958C for 15 s and 608C for 1 min. The real-time PCR of each sample were performed in duplicate. The data were analysed using the cycle threshold (2 
Fibroblast growth factor 21 measurement
Serum FGF21 concentrations were measured using a specific mouse ELISA kit (BioVendor, Candler, NC, USA).
Plasmid construction
The FGF21 promoter construct 2 1821/þ 10, which contains two putative PPAR-a binding sites (16) , was amplified from mouse genomic DNA by PCR with sequence-specific primers containing Kpn I and Xho I restriction sites at their 5 0 -ends (forward 5 0 -ATGGTACCTCAGGTTCTATGCACGTTCC-3 0 and reverse 5 0 -ATCTCGAGAAGGCTGTCTGGTGAACGCA-3 0 ). The PCR product was digested with restriction enzymes Kpn I and Xho I, and cloned into the promoter-less luciferase reporter vector pGL2-basic (Promega) to generate the plasmid pGL2B-mFGF21P. The insert for PPAR-a over-expression was amplified from mouse liver cDNA by PCR using forward primer (5 0 -ATGCTAGCCCAACATGGTGGACACAGAG-3 0 ) con- 
Transfections and luciferase assays
The Chinese hamster ovary cell line cells were grown in MEM as described previously. The cells were seeded in twenty-fourwell plates at a density of 5 £ 10 4 cells per well and cultured for 24 h. Then the cells were transfected with 500 ng of mouse FGF21 promoter construct pGL2B-mFGF21P, 500 ng of mouse PPAR-a expression plasmid pcDNA3.1-mPPAR-a and 1 ng of pRL-CMV (Promega) per well, using FuGENE6 (Roche Applied Science, Indianapolis, IN, USA). At 24 h after the transfection, the medium was replaced by serumfree MEM, and the cells were further cultured for 8 h. Subsequently, the cells were treated with 100 mM-t-10, c-12-CLA or BSA for 16 h. Cell lysis and dual-luciferase assay were performed using the Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer's instructions. The luciferase activity expressed from a promoter construct was divided by that from pRL-CMV in the same well to normalise the variation in transfection efficiency.
Statistical analyses
All statistical analyses were performed using SAS software (SAS Institute, Cary, NC, USA). Comparisons between the two means were analysed using the t test. Multiple means were compared using ANOVA followed by Tukey's test. The data are expressed as means with their standard errors. P values, 0·05 were considered significant.
Results
The trans-10, cis-12-conjugated linoleic acid induced hepatic fibroblast growth factor 21 expression
To understand whether t-10, c-12-CLA treatment induces hepatic FGF21 expression, HepG2 cells were cultured with t-10, c-12-CLA (10 mM or 100 mM). Real-time RT-PCR analysis indicated that the relative abundance of FGF21 mRNA was significantly induced by 100 mM-t-10, c-12-CLA in vitro (P, 0·05; Fig. 1(a) ). CLA at a low dosage (10 mM) also improved FGF21 mRNA levels ( Fig. 1(a) ), but no statistical significance was observed (P¼0·26). The animal experiment was then conducted to examine the effects of t-10, c-12-CLA on hepatic FGF21 expression in vivo. Dietary t-10, c-12-CLA significantly stimulated the relative FGF21 mRNA expression in the mouse livers (P, 0·01; Fig. 1(b) ). ELISA measurement showed that t-10, c-12-CLA administration significantly increased serum concentrations of FGF21 protein (P,0·05; Fig. 1(c) ).
The trans-10, cis-12-conjugated linoleic acid activated the fibroblast growth factor 21 promoter in a PPAR-adependent manner
To determine whether t-10, c-12-CLA activates the mouse FGF21 promoter, a co-transfection analysis was applied. The administration of t-10, c-12-CLA (100 mM) significantly increased the luciferase activity expressed from the transfected mouse FGF21 promoter in the Chinese hamster ovary cells (P,0·05; Fig. 2 ). To investigate whether PPAR-a contributes to the response of the FGF21 promoter to t-10, c-12-CLA treatment, an empty pcDNA3.1 vector was used in the co-transfection analysis instead of PPAR-a expression plasmid pcDNA3.1-mPPAR-a. The absence of PPAR-a abolished the response of the FGF21 promoter to t-10, c-12-CLA (P, 0·05; Fig. 2 ). 
Discussion
Since obesity is becoming more prevalent these days, people are increasingly interested in the strategies of reducing body weight. Research during the past decades has reported that supplementation with either a CLA mixture or t-10, c-12-CLA alone decreases body fat mass and body weight in various animal models and in some human studies (17 -19) . Thus, CLA, especially t-10, c-12-CLA, is perceived as a potential therapeutic candidate for obesity reduction. The possible mechanisms by which t-10, c-12-CLA reduces adiposity include (1) decreasing energy intake by suppressing appetite; (2) increasing energy expenditure in white adipose tissue, muscle and liver tissue; (3) decreasing lipogenesis and increasing lipolysis; and (4) inducing adipocytes apoptosis via endoplasmic reticulum stress, inflammation and/or insulin resistance (20) . The present study showed that t-10, c-12-CLA up-regulated hepatic FGF21 expression (Fig. 1) . FGF21 is known as a regulative hormone related to adiposity control (5) .
FGF21 can increase energy expenditure in diet-induced obese mice (6) , and FGF21 knockout results in impaired lipolysis in white adipose tissue (21) . However, recent studies in human subjects showed that circulating FGF21 concentrations exhibit a circadian rhythm and are associated with hepatic steatosis and TAG (22 -24) . Overfeeding that caused liver steatosis also induces hepatic FGF21 expression in mice (25) . Interestingly, FGF21 has been shown to reverse hepatic steatosis (6) . Therefore, feedback regulation between steatosis and FGF21 might exist. It is probable that FGF21 is a biomarker for fatty liver, whereas increased FGF21 could reverse hepatic steatosis. Taken together, although the exact role of FGF21 in CLA correction of obesity remains unclear, the present results suggested that FGF21 might be a downstream regulator that was involved in the anti-obesity effect of CLA. Feed intakes and body weight changes in mice in the animal experiment were not monitored because of the short experiment period. We initiated the present study for repeating the induction of t-10, c-12-CLA on the hepatic FGF21 expression in vivo. These data provided us new insight into the anti-obesity effect of CLA. However, further studies are still required to understand more about the anti-obesity mechanisms.
Treatment of t-10, c-12-CLA activated the FGF21 promoter, whereas the absence of PPAR-a abolished the response of the FGF21 promoter to CLA (Fig. 2) . This finding demonstrated that CLA regulates FGF21 transcription through PPAR-a in the liver. Although t-10, c-12-CLA is proved as a ligand of PPAR-a and PPAR-b/d (13) , t-10, c-12-CLA decreases the expression and activity of PPAR-g in the adipose tissue (12, 26) . FGF21 is one of the PPAR-a target genes in the liver (2) , but adipose FGF21 is regulated by PPAR-g (27) . Therefore, FGF21 may act in an endocrine manner to mediate the anti-obesity effects of CLA.
In conclusion, the present results indicate that t-10, c-12-CLA induces hepatic FGF21 expression through PPAR-a. The linkage between FGF21 and PPAR-a may provide another potential explanation for the anti-obesity effect of t-10, c-12-CLA and warrants further investigation.
